EXOSENS – Trademark Portfolio

Entity Type: 34

EXOSENS holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 1 filings in this category. The portfolio also extends into Class 9 (Computers & Electronics) across 3 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include EXOSENS.

Domaine de Pelus,

18 Avenue de Pythagore Axis, Business Park Bat 5e F-33700 MERIGNAC

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

EXOSENS
EXOSENS
Registered 2024

Trademark Classifications

EXOSENS's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

42
Computer & Scientific (1 filing)

Scientific and technological services; industrial analysis and research services

9
Computers & Electronics (1 filing)

Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments

10
Medical Apparatus (1 filing)

Surgical, medical, dental and veterinary apparatus and instruments

Frequently Asked Questions

How many trademarks does EXOSENS have?

EXOSENS has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does EXOSENS file in?

EXOSENS files trademarks across 3 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus). Class 42 covers scientific and technological services; industrial analysis and research services.

What are EXOSENS's most well-known trademarks?

EXOSENS's registered trademark portfolio includes well-known marks such as EXOSENS. These are among 1 currently registered trademark in the portfolio.

What is EXOSENS's trademark registration success rate?

EXOSENS has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.